BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013; 19(40): 6703-6709 [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Sims OT, Maynard QR, Melton PA. Behavioral Interventions to Reduce Alcohol Use Among Patients with Hepatitis C: A Systematic Review. Soc Work Public Health 2016;31:565-73. [PMID: 27295132 DOI: 10.1080/19371918.2016.1160346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, Thomas DL, Mehta SH. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int 2020;40:2407-16. [PMID: 32770638 DOI: 10.1111/liv.14634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60-89. [PMID: 24713006 DOI: 10.1111/jvh.12249] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 17.4] [Reference Citation Analysis]
4 Pourmarzi D, Hall L, Smirnov A, Hepworth J, Rahman T, Fitzgerald G. Framework for community-based models for treating hepatitis C virus. Aust Health Review 2020;44:459. [DOI: 10.1071/ah18220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, Perrier A, Negro F. Drug Pricing Evolution in Hepatitis C. PLoS One 2016;11:e0157098. [PMID: 27310294 DOI: 10.1371/journal.pone.0157098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
6 Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixko C, Decaestecker J, De Galocsy C, Janssens F, Cool M, Van Overbeke L, Van Steenkiste C, D'heygere F, Cools W, Nevens F, Robaeys G. Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend 2017;177:214-20. [PMID: 28618285 DOI: 10.1016/j.drugalcdep.2017.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
7 Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol 2015; 7(15): 1921-1935 [PMID: 26244067 DOI: 10.4254/wjh.v7.i15.1921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765 [PMID: 25349647 DOI: 10.4254/wjh.v6.i10.759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Bass SB, Jessop A, Maurer L, Gashat M, Al Hajji M, Gutierrez M. Mapping the Barriers and Facilitators of HCV Treatment Initiation in Methadone Maintenance Therapy Patients: Implications for Intervention Development. J Health Commun 2018;23:117-27. [PMID: 29252118 DOI: 10.1080/10810730.2017.1414902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
10 Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963 [PMID: 26244069 DOI: 10.4254/wjh.v7.i15.1953] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
11 Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd. Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 2020;15:e0228471. [PMID: 32023310 DOI: 10.1371/journal.pone.0228471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
12 Li X, Chan NS, Tam AW, Hung IFN, Chan EW. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis. 2017;36:1801-1809. [PMID: 28516201 DOI: 10.1007/s10096-017-2995-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
13 Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol 2017; 23(26): 4669-4674 [PMID: 28765688 DOI: 10.3748/wjg.v23.i26.4669] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
14 Wang Z, Grundy Q, Parker L, Bero L. Health promoter, advocate, legitimiser - the many roles of WHO guidelines: a qualitative study. Health Res Policy Syst 2019;17:96. [PMID: 31805956 DOI: 10.1186/s12961-019-0489-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Seear K. Addressing alcohol and other drug stigma: Where to next? Drug Alcohol Rev 2019;39:109-13. [DOI: 10.1111/dar.13028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, Hatzakis A, Prins M, Vickerman P, Lazarus JV. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9:e103345. [PMID: 25068274 DOI: 10.1371/journal.pone.0103345] [Cited by in Crossref: 151] [Cited by in F6Publishing: 142] [Article Influence: 18.9] [Reference Citation Analysis]
17 Reygosa C, Morales-Arraez D, Hernández-Bustabad A, Melián Baute L, Hernández-Guerra M. Hepatitis C-treated patients as a potential source for referral of new cases. Gastroenterol Hepatol 2021:S0210-5705(21)00148-5. [PMID: 34023471 DOI: 10.1016/j.gastrohep.2021.03.006] [Reference Citation Analysis]
18 Sims OT, Melton PA, Ji S. A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients. J Community Health 2018;43:725-30. [PMID: 29511988 DOI: 10.1007/s10900-018-0476-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Mohamoud YA, Miller FD, Abu-Raddad LJ. Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: An analysis using hepatitis C virus as a proxy biomarker. World J Gastroenterol 2014; 20(36): 12734-12752 [PMID: 25278675 DOI: 10.3748/wjg.v20.i36.12734] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
20 Yu L, Wang J, Zhu D, Leng A, Wangen KR. Hepatitis B-related knowledge and vaccination in association with discrimination against Hepatitis B in rural China. Hum Vaccin Immunother 2016;12:70-6. [PMID: 26211570 DOI: 10.1080/21645515.2015.1069932] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
21 Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. BMC Infect Dis 2016;16:565. [PMID: 27733137 DOI: 10.1186/s12879-016-1883-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
22 Taft TH, Keefer L. A systematic review of disease-related stigmatization in patients living with inflammatory bowel disease. Clin Exp Gastroenterol 2016;9:49-58. [PMID: 27022294 DOI: 10.2147/CEG.S83533] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
23 Harikishore A, Li E, Lee JJ, Cho NJ, Yoon HS. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Mol Divers 2015;19:529-39. [PMID: 25862642 DOI: 10.1007/s11030-015-9591-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Wojcik EM, Sharon MJ, Davis SM, Lander OM, Burrell CN. Centers for Disease Control and Prevention Recommendations for Hepatitis C Testing: The Need to Adopt Universal Screening in an Appalachian Emergency Department. Acad Emerg Med 2020;27:844-52. [PMID: 32017316 DOI: 10.1111/acem.13932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Surratt HL, Otachi JK, Mclouth CJ, Vundi N. Healthcare stigma and HIV risk among rural people who inject drugs. Drug and Alcohol Dependence 2021;226:108878. [DOI: 10.1016/j.drugalcdep.2021.108878] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: Molecular basis and therapeutic options. World J Gastroenterol 2014; 20(21): 6457-6469 [PMID: 24914367 DOI: 10.3748/wjg.v20.i21.6457] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
27 de Avila L, Weinstein AA, Estep JM, Curry MP, Golabi P, Escheik C, Birerdinc A, Stepanova M, Gerber L, Younossi ZM. Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. Liver Int 2019;39:1631-40. [PMID: 30959554 DOI: 10.1111/liv.14115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T. Increased hope following successful treatment for hepatitis C infection. J Adv Nurs 2018;74:724-33. [PMID: 29082540 DOI: 10.1111/jan.13487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Cho HJ, Park E. Quality of Life of Chronic Hepatitis C Patients and Its Associated Factors. Osong Public Health Res Perspect 2017;8:124-9. [PMID: 28540156 DOI: 10.24171/j.phrp.2017.8.2.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Biomy R, Abdelshafy M, Abdelmonem A, Abu-Elenin H, Ghaly G. Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. Clin Med Insights Cardiol 2017;11:1179546817713204. [PMID: 28804248 DOI: 10.1177/1179546817713204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
31 Macbeth K, Davidson K, Anderson J. Treating hepatitis C in a dedicated GP practice for homeless patients: a multidisciplinary approach. Gastrointestinal Nursing 2018;16:S29-36. [DOI: 10.12968/gasn.2018.16.sup10.s29] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Leng A, Li Y, Wangen KR, Nicholas S, Maitland E, Wang J. Hepatitis B discrimination in everyday life by rural migrant workers in Beijing. Hum Vaccin Immunother 2016;12:1164-71. [PMID: 27043963 DOI: 10.1080/21645515.2015.1131883] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cardoso H, Silva M. Health-Related Quality of Life in Chronic Hepatitis C. GE Port J Gastroenterol 2017;24:55-7. [PMID: 28848783 DOI: 10.1159/000453319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Karmarkar T, Rodriguez-Watson CV, Watson E, Zheng H, Gaskin DJ, Padula WV. Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis. Value Health 2022:S1098-3015(22)00145-0. [PMID: 35484030 DOI: 10.1016/j.jval.2022.03.003] [Reference Citation Analysis]
35 Falcão EM, Trope BM, Godinho MM, Carneiro LH, de Araujo-Neto JM, Nogueira CA, Ramos-E-Silva M. Cutaneous Eruption due to Telaprevir. Case Rep Dermatol 2015;7:253-62. [PMID: 26500538 DOI: 10.1159/000439264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
36 Rei A, Rocha M, Pedroto I. Health-Related Quality of Life in Portuguese Patients with Chronic Hepatitis C. GE Port J Gastroenterol 2017;24:68-78. [PMID: 28848786 DOI: 10.1159/000450875] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Childs E, Assoumou SA, Biello KB, Biancarelli DL, Drainoni ML, Edeza A, Salhaney P, Mimiaga MJ, Bazzi AR. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs. Harm Reduct J 2019;16:14. [PMID: 30744628 DOI: 10.1186/s12954-019-0286-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Queiroga Mde L, Paraná R, Medeiros Filho JE, Figueiredo GC, Araújo AP, Leite HW, Aquino Ide S, Melo Neto LH. GAMMA GLUTAMYLTRANSFERASE IMPACT IN THERAPEUTIC RESPONSE OF CHRONIC HEPATITIS C: a systematic review of the literature. Arq Gastroenterol 2015;52:239-46. [PMID: 26486294 DOI: 10.1590/S0004-28032015000300016] [Reference Citation Analysis]
39 Talal AH, Jaanimägi U, Davis K, Bailey J, Bauer BM, Dharia A, George S, McLeod A, Morton K, Nugent A, Zeremski M, Dinani A, Des Jarlais DC, Perumalswami PV, Tobin JN, Dickerson SS. Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. J Subst Abuse Treat 2021;127:108421. [PMID: 34134875 DOI: 10.1016/j.jsat.2021.108421] [Reference Citation Analysis]
40 Chiauzzi E, DasMahapatra P, Cochin E, Bunce M, Khoury R, Dave P. Factors in Patient Empowerment: A Survey of an Online Patient Research Network. Patient 2016;9:511-23. [PMID: 27155887 DOI: 10.1007/s40271-016-0171-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
41 Olmedo DB, Precioso PM, Lugdero-Correia A, Silva GD, Santos AMGD, Pôrto LC. Exposure source prevalence is associated with gender in hepatitis C virus patients from Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 2017;112:632-9. [PMID: 28902289 DOI: 10.1590/0074-02760160553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
42 Anjo J, Café A, Carvalho A, Doroana M, Fraga J, Gíria J, Marinho R, Santos S, Velosa J. O impacto da hepatite C em Portugal. GE Jornal Português de Gastrenterologia 2014;21:44-54. [DOI: 10.1016/j.jpg.2014.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
43 Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend 2015;153:66-71. [PMID: 26096534 DOI: 10.1016/j.drugalcdep.2015.06.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
44 Smith DE, Chen S, Fargnoli A, Lewis T, Galloway AC, Kon ZN, Moazami N. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors. Semin Thorac Cardiovasc Surg 2021;33:407-15. [PMID: 32621962 DOI: 10.1053/j.semtcvs.2020.06.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Duffell EF, Hedrich D, Mardh O, Mozalevskis A. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions. Euro Surveill 2017;22:30476. [PMID: 28277217 DOI: 10.2807/1560-7917.ES.2017.22.9.30476] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
46 Mohanty P, Jena P, Patnaik L. Vaccination against Hepatitis B: A Scoping Review. Asian Pac J Cancer Prev 2020;21:3453-9. [PMID: 33369439 DOI: 10.31557/APJCP.2020.21.12.3453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Sims OT, Gupta J, Missmer SA, Aninye IO. Stigma and Endometriosis: A Brief Overview and Recommendations to Improve Psychosocial Well-Being and Diagnostic Delay. Int J Environ Res Public Health 2021;18:8210. [PMID: 34360501 DOI: 10.3390/ijerph18158210] [Reference Citation Analysis]
48 Pourmarzi D, Hall L, Rahman T, Lim D, Fitzgerald G. Clinical effectiveness, cost-effectiveness and acceptability of community-based management of chronic hepatitis C: a mixed methods systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 2017;15:914-31. [DOI: 10.11124/jbisrir-2016-003103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
49 Barreira DP, Marinho RT, Bicho M, Fialho R, Ouakinin SRS. Psychosocial and Neurocognitive Factors Associated With Hepatitis C - Implications for Future Health and Wellbeing. Front Psychol 2018;9:2666. [PMID: 30687151 DOI: 10.3389/fpsyg.2018.02666] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
50 Ly W, Cocohoba J, Chyorny A, Halpern J, Auerswald C, Myers J. Perspectives on Integrated HIV and Hepatitis C Virus Testing Among Persons Entering a Northern California Jail: A Pilot Study. J Acquir Immune Defic Syndr 2018;78:214-20. [PMID: 29474267 DOI: 10.1097/QAI.0000000000001664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Pericot-valverde I, Heo M, Niu J, Rennert L, Norton BL, Akiyama MJ, Arnsten J, Litwin AH. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder. Drug and Alcohol Dependence 2022;234:109403. [DOI: 10.1016/j.drugalcdep.2022.109403] [Reference Citation Analysis]
52 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd. Determinants of stigma among patients with hepatitis C virus infection. J Viral Hepat 2020;27:1179-89. [PMID: 32500618 DOI: 10.1111/jvh.13343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]